ArticleViruses2015
Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid.
Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Antiviral Inactivated Vaccines: Looking to the Past to Face the Future-A Narrative Review.Vaccines · 2025Review
- Virucidal Approaches for Hemorrhagic Fever Viruses.Viruses · 2025Review
- Article
- Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenicMicrobiology spectrum · 2024Article
- Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID-19: An early phase 1 descriptive study.Health science reports · 2024Article
- The Immunogenicity and Properties of a Whole-Cell ETEC Vaccine Inactivated with Psoralen and UVA Light in Comparison to Formalin.Microorganisms · 2023Article
- Psoralen inhibits hepatitis B viral replication by down-regulating the host transcriptional machinery of viral promoters.Virologica Sinica · 2022Article
- Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes.Pathogens (Basel, Switzerland) · 2022Review
- Article
- Focused role of nanoparticles against COVID-19: Diagnosis and treatment.Photodiagnosis and photodynamic therapy · 2021Review
- Validation of Inactivation Methods for Arenaviruses.Viruses · 2021Article
- Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.Current protocols in cytometry · 2020Article
- Oxygen-Independent Antimicrobial Photoinactivation: Type III Photochemical Mechanism?Antibiotics (Basel, Switzerland) · 2020Review
- Psoralen Derivatives: Recent Advances of Synthetic Strategy and Pharmacological Properties.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020Review
- A Review of the Pharmacological Properties of Psoralen.Frontiers in pharmacology · 2020Review
- De Novo Isolation & Affinity Maturation of yeast-displayed Virion-binding human fibronectin domains by flow cytometric screening against Virions.Journal of biological engineering · 2019Article
- Photochemical Treatment ofMediators of inflammation · 2018Article
- Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization - a Thomas Dougherty Award for Excellence in PDT paper.Journal of porphyrins and phthalocyaninesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High consequence human pathogenic viruses must be handled at biosafety level 2, 3 or 4 and must be rendered non-infectious before they can be utilized for molecular or immunological applications at lower biosafety levels. Here we evaluate psoralen-inactivated Arena-, Bunya-, Corona-, Filo-, Flavi- and Orthomyxoviruses for their suitability as antigen in immunological processes and as template for reverse transcription PCR and sequencing. The method of virus inactivation using a psoralen molecule appears to have broad applicability to RNA viruses and to leave both the particle and RNA of the treated virus intact, while rendering the virus non-infectious.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.